Kura Oncology, Inc.
KURAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeKura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. At a $854.9M market cap, Kura Oncology, Inc. ranks as a small-cap company within healthcare. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.
Market Cap
$854.9M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-4.09
EPS (TTM)
$-3.37
EPS (Fwd)
$-2.35
ROE
-167.7%
ROA
-31.3%
Cash
$519.0M
Total Debt
$24.5M
Free CF
-$165.9M
52W Change
-13.0%
Annual Financials
Cash vs Debt
Where KURA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KURA finished 7.87% below its 150-day moving average ($10.16) and 4.29% below its 200-day moving average ($9.78). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KURA overbought or oversold?
At the October 20, 2026 close, KURA's RSI(14) was 22.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $519.0M in cash comfortably exceeding the $24.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$165.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -167.7%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
KURA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kura Oncology, Inc. and its sector.